Have a personal or library account? Click to login
Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer Cover

Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer

Radiology and Oncology
Volume 56 (2022): Issue 2 (June 2022)
By: Jiwon Choi,  Jiyoung Park,  Ilyoung Cho and  Yhunyhong Sheen  
Open Access
|Apr 2022

Authors

Jiwon Choi

College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea
National Center for Efficacy Evaluation for Respiratory Disease Products, Korea Institute of Toxicology, Seoul, Republic of Korea

Jiyoung Park

College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea
National Center for Efficacy Evaluation for Respiratory Disease Products, Korea Institute of Toxicology, Seoul, Republic of Korea

Ilyoung Cho

College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea

Yhunyhong Sheen

yysheen@ewha.ac.kr

College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea
DOI: https://doi.org/10.2478/raon-2022-0012 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 185 - 197
Submitted on: Sep 26, 2021
Accepted on: Jan 28, 2022
Published on: Apr 7, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
vactosertib,
transforming growth factor-β (TGF-β),
radiotherapy,
epithelial-to-mesenchymal transition,
cancer stem cell,
breast cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2022 Jiwon Choi, Jiyoung Park, Ilyoung Cho, Yhunyhong Sheen, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 56 (2022): Issue 2 (June 2022)Next article